贝伐单抗
医学
胶质母细胞瘤
放射治疗
肿瘤科
替莫唑胺
内科学
胶质瘤
化疗
癌症研究
作者
Harjus Birk,Seunggu J. Han,Nicholas Butowski
出处
期刊:CNS oncology
[Future Medicine]
日期:2016-12-21
卷期号:6 (1): 61-70
被引量:70
标识
DOI:10.2217/cns-2016-0013
摘要
High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.
科研通智能强力驱动
Strongly Powered by AbleSci AI